Not all angiopoietin-like proteins (Angptls) are created equal: Insights from molecular, genetic, and pharmacological studies on the mechanism of LPL inhibition by Angptl3 and Angptl4

Current Opinion in Lipidology

Volumn 20, Issue 4, 2009, Pages 357-359

  Li, Cai ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; ANGIOPOIETIN LIKE PROTEIN 3; ANGIOPOIETIN LIKE PROTEIN 4; ESTERASE INHIBITOR; GLUTAMIC ACID; GLUTAMINE; HISTIDINE; LIPOPROTEIN LIPASE; LYSINE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALLELE; AMINO ACID SEQUENCE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE SEQUENCE; HUMAN; LIPID METABOLISM; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; SEQUENCE ANALYSIS; STRUCTURE ANALYSIS; TRIACYLGLYCEROL BLOOD LEVEL;

ANGIOPOIETINS; ENZYME INHIBITORS; HUMANS; LIPOPROTEIN LIPASE;

EID: 68449095061     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32832dd55a     Document Type: Note

References (12)

1. Romeo S, Pennacchio LA, Fu Y, et al. Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL. Nat Genet 2007; 39:513-516.
2. Shan L, Yu XC, Liu Z, et al. The angiopoietin-like proteins ANGPTL3 and ANGPTL4 inhibit lipoprotein lipase activity through distinct mechanisms. J Biol Chem 2009; 284:1419-1424.
3. Ge H, Yang G, Huang L, et al. Oligomerization and regulated proteolytic processing of angiopoietin-like protein 4. J Biol Chem 2004; 279:2038-2045.
4. Ge H, Yang G, Yu X, et al. Oligomerization state-dependent hyperlipidemic effect of angiopoietin-like protein 4. J Lipid Res 2004; 45:2071-2079.
5. Yin W, Romeo S, Chang S, et al. Genetic variation in ANGPTL4 provides insights into protein processing and function. J Biol Chem 2009; 284: 13213-13222.
6. Yau MH, Wang Y, Lam KS, et al. A highly conserved motif within the NH2 terminal coiled-coil domain of angiopoietin-like protein 4 confers its inhibitory effects on lipoprotein lipase through disrupting the enzyme dimerization. J Biol Chem 2009; 284:11942-11952.
7. Lee EC, Desai U, Gololobov G, et al. Identification of a new functional domain in angiopoietin-like 3 (ANGPTL3) and angiopoietin-like 4 (ANGPTL4) involved in binding and inhibition of lipoprotein lipase (LPL). J Biol Chem 2009; 284:13733-13745.
8. Desai U, Lee EC, Chung K, et al. Lipid-lowering effects of antiangiopoietin-like 4 antibody recapitulate the lipid phenotype found in angiopoietin-like 4 knockout mice. Proc Natl Acad Sci U S A 2007; 104:11766-11771.
9. Romeo S, Yin W, Kozlitina J, et al. Rare loss-of-function mutations in ANGPTL family members contribute to plasma triglyceride levels in humans. J Clin Invest 2009; 119:70-79.
10. Yang YH, Wang Y, Lam KS, et al. Suppression of the Raf/MEK/ERK signalling cascade and inhibition of angiogenesis by the carboxyl terminus of angiopoietin-like protein 4. Arterioscler Thromb Vasc Biol 2008; 28:835-840.
11. Talmud PJ, Smart M, Presswood E, et al. ANGPTL4 E40K and T266M: effects on plasma triglyceride and HDL levels, postprandial responses, and CHD risk. Arterioscler Thromb Vasc Biol 2008; 28:2319-2325.
12. Nettleton JA, Volcik KA, Demerath EW, et al. Longitudinal changes in triglycerides according to ANGPTL4[E40K] genotype and longitudinal body weight change in the atherosclerosis risk in communities study. Ann Epidemiol 2008; 18:842-846.